Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)

NCT03524430 is registered in ClinicalTrials.gov with Rna Diagnostics Inc. as lead sponsor.

NCT NCT03524430
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03524430 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY / BREVITY-02 in Germany)
Lead sponsor
Rna Diagnostics Inc.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
April 26, 2018
Completion date
May 22, 2031
Enrollment
801 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasm female